- Home
- MAPS vs AGEN Comparison
MAPS vs AGEN Comparison
Compare MAPS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAPS
- AGEN
- Stock Information
- Founded
- MAPS 2008
- AGEN 1994
- Country
- MAPS United States
- AGEN United States
- Employees
- MAPS N/A
- AGEN N/A
- Industry
- MAPS Computer Software: Prepackaged Software
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAPS Technology
- AGEN Health Care
- Exchange
- MAPS Nasdaq
- AGEN Nasdaq
- Market Cap
- MAPS 106.3M
- AGEN 126.8M
- IPO Year
- MAPS N/A
- AGEN 2000
- Fundamental
- Price
- MAPS $0.79
- AGEN $4.24
- Analyst Decision
- MAPS Strong Buy
- AGEN Buy
- Analyst Count
- MAPS 1
- AGEN 2
- Target Price
- MAPS $2.61
- AGEN $14.50
- AVG Volume (30 Days)
- MAPS 862.1K
- AGEN 460.1K
- Earning Date
- MAPS 11-06-2025
- AGEN 11-10-2025
- Dividend Yield
- MAPS N/A
- AGEN N/A
- EPS Growth
- MAPS N/A
- AGEN N/A
- EPS
- MAPS 0.07
- AGEN N/A
- Revenue
- MAPS $179,305,000.00
- AGEN $106,829,000.00
- Revenue This Year
- MAPS N/A
- AGEN $60.49
- Revenue Next Year
- MAPS $5.43
- AGEN N/A
- P/E Ratio
- MAPS $10.75
- AGEN N/A
- Revenue Growth
- MAPS N/A
- AGEN N/A
- 52 Week Low
- MAPS $0.74
- AGEN $1.38
- 52 Week High
- MAPS $1.65
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- MAPS 28.47
- AGEN 51.52
- Support Level
- MAPS $0.89
- AGEN $4.17
- Resistance Level
- MAPS $0.98
- AGEN $4.49
- Average True Range (ATR)
- MAPS 0.06
- AGEN 0.28
- MACD
- MAPS -0.02
- AGEN 0.03
- Stochastic Oscillator
- MAPS 21.04
- AGEN 55.19
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises the B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on marketplace ads.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).